Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, announced that it has entered into a definitive arrangement agreement (“Arrangement Agreement”) to acquire Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (“Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. Since its inception in 2015, Appili has developed a diverse portfolio, including the FDA-approved LIKMEZ™ (previously ATI-1501), ATI-1701 biodefense program supported by a USD $14 million non-dilutive award from the U.S DoD., and ATI-1801, a topical formulation targeting cutaneous leishmaniasis, a painful and disfiguring disease.
Read the full article: Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc. //
Source: https://www.businesswire.com/news/home/20240402301815/en/Aditxt-Signs-a-Definitive-Agreement-to-Acquire-Appili-Therapeutics-Inc.-Developer-of-a-Biodefense-Vaccine-Funded-by-the-U.S.-Department-of-Defense-DoD